ERBB2 and breast carcinoma: These data indicate that the intrinsically fluorescenttetravalent TetraFHER2-vcMMAE conjugate, by promoting aggregation-dependentendocytosis of HER2, serves as a highly selective and efficient drugcarrier for targeted treatment of HER2+ breast cancer cells.